Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gujarat Themis BiosynNSE:GUJTHEM -1.73%65 EV-to-EBITDA is 66.92 as of Sep. 15, 2026, which is 479% above its 10-year median of 11.56. GuruFocus rates NSE:GUJTHEM with a GF Score™ of 65/100 and a GF Value™ of ₹352.46 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 728 Drug Manufacturers companies, Gujarat Themis Biosyn ranks worse than 92.58% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Gujarat Themis Biosyn's enterprise value is ₹56,677 Mil.
Gujarat Themis Biosyn's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹847 Mil. Therefore, Gujarat Themis Biosyn's EV-to-EBITDA for today is 66.92.
The historical rank and industry rank for Gujarat Themis Biosyn's EV-to-EBITDA or its related term are showing as below:
NSE:GUJTHEM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.37 Med: 11.56 Max: 1445.76
Current: 66.92
During the past 13 years, the highest EV-to-EBITDA of Gujarat Themis Biosyn was 1445.76. The lowest was 3.37. And the median was 11.56.
NSE:GUJTHEM's EV-to-EBITDA is ranked worse than 92.58% of 728
companies
in the Drug Manufacturers industry
Industry Median: 13.375
vs NSE:GUJTHEM: 66.92
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gujarat Themis Biosyn's PE Ratio (TTM) for today is calculated as:
Gujarat Themis Biosyn's share price for today is ₹422.65.
Gujarat Themis Biosyn's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4.470.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Gujarat Themis Biosyn EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Gujarat Themis Biosyn's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gujarat Themis Biosyn's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gujarat Themis Biosyn EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gujarat Themis Biosyn's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Gujarat Themis Biosyn's EV-to-EBITDA falls into.
Gujarat Themis Biosyn's current Enterprise Value is ₹56,677 Mil.
Gujarat Themis Biosyn's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹847 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gujarat Themis Biosyn (NSE:GUJTHEM) has a EV-to-EBITDA of 66.92 as of Sep. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Gujarat Themis Biosyn. This is 479% above median its historical median of 11.56. Over the past decade, Gujarat Themis Biosyn's EV-to-EBITDA has ranged from 3.37 to 1,445.76. According to the industry distribution chart, Gujarat Themis Biosyn ranks #674 out of 728 companies in the Drug Manufacturers industry, placing it in the top 92.6%.
Is Gujarat Themis Biosyn's EV-to-EBITDA too high?
Gujarat Themis Biosyn's current EV-to-EBITDA of 66.92 is 479% above median its 10-year median of 11.56. Over the past 10 years, this metric has ranged from a low of 3.37 to a high of 1,445.76. The Drug Manufacturers industry median EV-to-EBITDA is 13.38. Gujarat Themis Biosyn's value of 66.92 is 400.3% above this industry median. Based on the distribution chart, Gujarat Themis Biosyn ranks #674 out of 728 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Gujarat Themis Biosyn has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gujarat Themis Biosyn's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Gujarat Themis Biosyn ranks #674 out of 728 companies for EV-to-EBITDA. This places Gujarat Themis Biosyn in the lower half of its industry. The industry median EV-to-EBITDA is 13.38. Gujarat Themis Biosyn's value of 66.92 is 400.3% above this benchmark. Historically, Gujarat Themis Biosyn's own EV-to-EBITDA has ranged from 3.37 to 1,445.76 over the past decade. While the company's 10-year median is 11.56 vs. the industry median of 13.38, Gujarat Themis Biosyn has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.38, based on 728 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gujarat Themis Biosyn's current EV-to-EBITDA of 66.92 is 400.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Gujarat Themis Biosyn. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gujarat Themis Biosyn's current EV-to-EBITDA is 66.92, which is 479% above median its own 10-year median of 11.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gujarat Themis Biosyn stock overvalued right now?
Based on GuruFocus' analysis, Gujarat Themis Biosyn (NSE:GUJTHEM) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹352.46, compared to a current price of ₹422.65 — trading 19.9% above its estimated fair value. The current EV-to-EBITDA is 66.92, which is 479% above median its 10-year median of 11.56 and 400.3% above the Drug Manufacturers industry median of 13.38. Gujarat Themis Biosyn's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Gujarat Themis Biosyn (NSE:GUJTHEM), the current EV-to-EBITDA is 66.92 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gujarat Themis Biosyn (NSE:GUJTHEM) Overvalued in 2026?
Based on GuruFocus' analysis, Gujarat Themis Biosyn stock appears to be overvalued.
The current stock price of ₹422.65 is trading 19.9% above its estimated GF Value™ of ₹352.46.
GuruFocus considers Gujarat Themis Biosyn to be Modestly Overvalued.
Key valuation signals for NSE:GUJTHEM:
EV-to-EBITDA: 66.92 (479% above median its 10-year median of 11.56)
GF Value™: ₹352.46 vs. price of ₹422.65 (19.9% above fair value)
Industry Position: 400.3% above the Drug Manufacturers median (#674 of 728)
No single metric tells the full story. See the NSE:GUJTHEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gujarat Themis Biosyn Ltd is engaged in manufacturing, exporting, and selling of bulk drugs on a job-work basis. The company operates in one segment which is pharmaceuticals. Its products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.
65GF Score
Get the complete analysis for NSE:GUJTHEM
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GUJTHEM has been successfully added to your 
